DOCSLIB.ORG

Sunitinib (Sutent) Reference Number: ERX.SPMN.118 Effective Date: 03/14 Coding Implications Last Review Date: 09/16 Revision Log

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sunitinib (Sutent) Reference Number: ERX.SPMN.118 Effective Date: 03/14 Coding Implications Last Review Date: 09/16 Revision Log Clinical Policy: Sunitinib (Sutent) Reference Number: ERX.SPMN.118 Effective Date: 03/14 Coding Implications Last Review Date: 09/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Policy/Criteria It is the policy of health plans affiliated with Envolve Pharmacy Solutions® that sunitinib (Sutent®) is medically necessary when one of the following criteria are met: I. Initial Approval Criteria A. Gastrointestinal Stromal Tumor (must meet all): 1. Diagnosis of gastrointestinal stromal tumor (GIST); 2. Member has demonstrated disease progression on or intolerance to imatinib mesylate; 3. Prescribed regimen of Sutent does not exceed 50 mg per day on a schedule of 4 weeks on treatment followed by 2 weeks off. Approval duration: 3 months B. Renal Cell Carcinoma (must meet all): 1. Diagnosis of renal cell carcinoma (RCC); 2. Member has relapsed or stage IV disease; 3. Prescribed regimen of Sutent does not exceed 50 mg per day on a schedule of 4 weeks on treatment followed by 2 weeks off. Approval duration: 3 months C. Pancreatic Neuroendocrine Tumors (must meet all): 1. Diagnosis of pancreatic neuroendocrine tumor (pNET); 2. pNET is unresectable locally advanced or metastatic; 3. Prescribed dose of Sutent does not exceed 50 mg per day. Approval duration: 3 months D. Other diagnoses/indications: Refer to ERX.SPMN.16 - Global Biopharm Policy. 1. Additional Sutent uses, as outlined in the NCCN compendium and meeting NCCN category 1, 2a, or 2b, are covered for the following indications per the ERX.SPMN.16 Global Biopharm Policy: a. Bone cancer- chordoma; b. Central nervous system cancers- meningiomas; c. Lung neuroendocrine tumors; d. Soft tissue sarcoma- alveolar soft part sarcoma (ASPS); e. Soft tissue sarcoma- angiosarcoma Page 1 of 4 CLINICAL POLICY Sunitinib f. Soft tissue sarcoma- solitary fibrous tumor/hemangiopericytoma; g. Thymomas and thymic carcinomas; h. Thyroid carcinoma- follicular carcinoma; i. Thyroid carcinoma- Hurthle cell carcinoma; j. Thyroid carcinoma- medullary carcinoma; k. Thyroid carcinoma- papillary carcinoma. II. Continued Approval A. All Indications (GIST, RCC, and pNET) (must meet all): 1. Currently receiving medication via health plan benefit or member has previously met all initial approval criteria; 2. Prescribed dosage regimen does not exceed the following: a. For GIST or RCC: 50 mg per day on a schedule of 4 weeks on treatment followed by 2 weeks off; b. For pNET: 50 mg per day. Approval duration: 6 months B. Other diagnoses/indications (must meet 1 or 2): 1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy; or 2. Refer to ERX.SPMN.16 - Global Biopharm Policy. Background Description/Mechanism of Action: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays. Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRβ, VEGFR2, KIT) in tumor xenografts expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit PDGFRβ- and VEGFR2-dependent tumor angiogenesis in vivo. Page 2 of 4 CLINICAL POLICY Sunitinib Formulations: Sutent is available in 12.5 mg, 25 mg, 37.5 mg, and 50 mg capsules for oral administration. FDA Approved Indications: Sutent is a multi-kinase inhibitor/oral capsule formulation indicated for the treatment of patients with: Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. Advanced renal cell carcinoma (RCC). Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. Appendices Appendix A: Abbreviation Key ASPS: alveolar soft part sarcoma CSF-1R: colony stimulating factor receptor Type 1 FLT3: Fms-like tyrosine kinase-3 GIST: gastrointestinal stromal tumor KIT: stem cell factor receptor PDGFR: platelet-derived growth factor receptors pNET: pancreatic neuroendocrine tumor RCC: renal cell carcinoma RET: glial cell-line derived neurotrophic factor receptor RTKs: receptor tyrosine kinases VEGFR: vascular endothelial growth factor receptors Coding Implications Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services. HCPCS Description Codes Reviews, Revisions, and Approvals Date Approval Date Policy created. 02/1 03/14 4 Policy converted to new template. 08/1 09/16 Removed all safety criteria. Added dosing criteria per PI. Modified 6 approval duration to 3 months for initial and 6 months for re-auth. Page 3 of 4 CLINICAL POLICY Sunitinib Reviews, Revisions, and Approvals Date Approval Date Added NCCN compendial uses that are approvable via global biopharm policy. RCC: clarified “advanced disease” as “relapsed or stage IV”. pNET: removed requirement for disease to be progressive. References 1. Sutent Prescribing Information. New York, NY: Pfizer Inc.; April 2015. Available at: http://www.sutent.com/. Accessed July 21, 2016. 2. Sunitinib malate. In: National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at www.NCCN.org. Accessed July 21, 2016. 3. Kidney Cancer (Version 3.2016). In: National Comprehensive Cancer Network Guidelines. Available at www.NCCN.org. Accessed July 25, 2016. 4. Neuroendocrine Tumors (Version 2.2016). In: National Comprehensive Cancer Network Guidelines. Available at www.NCCN.org. Accessed July 25, 2016. Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions. ©2016 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein. Page 4 of 4 .
Load more

Recommended publications
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • Antitumor Reactivity in Vitro Sorafenib Differentially Affect NK Cell The
    The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro This information is current as Matthias Krusch, Julia Salih, Manuela Schlicke, Tina of September 24, 2021. Baessler, Kerstin Maria Kampa, Frank Mayer and Helmut Rainer Salih J Immunol 2009; 183:8286-8294; ; doi: 10.4049/jimmunol.0902404 http://www.jimmunol.org/content/183/12/8286 Downloaded from References This article cites 44 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/183/12/8286.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro1 Matthias Krusch,2 Julia Salih,2 Manuela Schlicke,2 Tina Baessler, Kerstin Maria Kampa, Frank Mayer,3 and Helmut Rainer Salih3,4 Sunitinib and Sorafenib are protein kinase inhibitors (PKI) approved for treatment of patients with advanced renal cell cancer (RCC).
    [Show full text]
  • And Insulin-Like Growth Factor-I (IGF-I) in Regulating Human Erythropoiesis
    Leukemia (1998) 12, 371–381 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 The role of insulin (INS) and insulin-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions – comparison to other cytokines and growth factors J Ratajczak, Q Zhang, E Pertusini, BS Wojczyk, MA Wasik and MZ Ratajczak Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA The role of insulin (INS), and insulin-like growth factor-I (IGF- has been difficult to assess. The fact that EpO alone fails to I) in the regulation of human erythropoiesis is not completely stimulate BFU-E in serum-free conditions, but does do in understood. To address this issue we employed several comp- lementary strategies including: serum free cloning of CD34؉ serum containing cultures indicates that serum contains some cells, RT-PCR, FACS analysis, and mRNA perturbation with oli- crucial growth factors necessary for the BFU-E development. godeoxynucleotides (ODN). In a serum-free culture model, both In previous studies from our laboratory, we examined the ؉ INS and IGF-I enhanced survival of CD34 cells, but neither of role of IGF-I12 and KL9,11,13 in the regulation of early human these growth factors stimulated their proliferation. The influ- erythropoiesis. Both of these growth factors are considered to ence of INS and IGF-I on erythroid colony development was be crucial for the BFU-E growth.3,6,8,14 Unexpectedly, that dependent on a combination of growth factors used for stimul- + ating BFU-E growth.
    [Show full text]
  • Imatinib-Induced Interstitial Lung Disease and Sunitinib-Associated
    CASE Imatinib-induced interstitial lung disease and REPORT sunitinib-associated intra-tumour haemorrhage Herbert H Loong 龍浩鋒 Winnie Yeo 楊明明 An ethnically Chinese patient with newly diagnosed metastatic gastro-intestinal stromal tumour initially treated with imatinib mesylate developed severe interstitial lung disease. As his condition improved after cessation of imatinib mesylate and treatment with corticosteroids, he was started on sunitinib malate. His clinical course was then unfortunately complicated with intra-tumour bleeding. This case report illustrates the dilemmas and complexities associated with treating patients with gastro-intestinal stromal tumours with the new tyrosine kinase inhibitors. Case report A 63-year-old man was referred to our department in January 2007 after being diagnosed with a recurrent gastro-intestinal stromal tumour (GIST). He was initially diagnosed with a duodenal GIST in January 2000 on presenting with symptoms of anaemia. A workup, including upper endoscopy, revealed an ulcerative growth over the third and fourth part of the duodenum. A computed tomographic (CT) scan showed a 4.5 x 5.5 cm soft tissue mass over the same area. A duodenectomy and duodeno-jejunostomy were performed and a pathological examination of tissue removed at surgery confirmed a low-grade GIST (S-100 positive; 4.5 cm in size, mitosis 6/10 high-power field, c-KIT positive). The resection margins were clear so he was managed with routine follow-up and observation. An abdominal ultrasound performed in 2003 showed no evidence of metastases. He remained well until January 2007 when hepatomegaly was found during a physical examination. An abdominal CT scan showed multiple hypervascular tumour foci with cystic changes in both liver lobes.
    [Show full text]
  • The Tyrosine-Kinase Inhibitor Sunitinib Targets Vascular Endothelial (VE)-Cadherin: a Marker of Response to Antitumoural Treatment in Metastatic Renal Cell Carcinoma
    www.nature.com/bjc ARTICLE Translational Therapeutics The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma Helena Polena1, Julie Creuzet1, Maeva Dufies2, Adama Sidibé1, Abir Khalil-Mgharbel1, Aude Salomon1, Alban Deroux3, Jean-Louis Quesada4, Caroline Roelants1, Odile Filhol1, Claude Cochet1, Ellen Blanc5, Céline Ferlay-Segura5, Delphine Borchiellini6, Jean-Marc Ferrero6, Bernard Escudier7, Sylvie Négrier5, Gilles Pages8 and Isabelle Vilgrain1 BACKGROUND: Vascular endothelial (VE)-cadherin is an endothelial cell-specific protein responsible for endothelium integrity. Its adhesive properties are regulated by post-translational processing, such as tyrosine phosphorylation at site Y685 in its cytoplasmic domain, and cleavage of its extracellular domain (sVE). In hormone-refractory metastatic breast cancer, we recently demonstrated that sVE levels correlate to poor survival. In the present study, we determine whether kidney cancer therapies had an effect on VE- cadherin structural modifications and their clinical interest to monitor patient outcome. METHODS: The effects of kidney cancer biotherapies were tested on an endothelial monolayer model mimicking the endothelium lining blood vessels and on a homotypic and heterotypic 3D cell model mimicking tumour growth. sVE was quantified by ELISA in renal cell carcinoma patients initiating sunitinib (48 patients) or bevacizumab (83 patients) in the first-line metastatic setting (SUVEGIL and TORAVA trials). RESULTS: Human VE-cadherin is a direct target for sunitinib which inhibits its VEGF-induced phosphorylation and cleavage on endothelial monolayer and endothelial cell migration in the 3D model. The tumour cell environment modulates VE-cadherin functions through MMPs and VEGF. We demonstrate the presence of soluble VE-cadherin in the sera of mRCC patients (n = 131) which level at baseline, is higher than in a healthy donor group (n = 96).
    [Show full text]
  • Factor-The Controlling Growth Factor-At a Sufficiently Low Value, While the Cell Population Has Ceased to Grow and Is in a Sort
    708 GENETICS: NO VICK A ND SZILARD PROC. N. A. S. EXPERIMENTS WITH THE CHEMOSTAT ON SPONTANEOUS MUTATIONS OF BACTERIA By AARON NOVICK AND LEO SZILARD INSTITUTRE OF RADIOBIOLOGY AND BIOPHYSICS, UNIVERSITY OF CHICAGO Communicated by H. J. Muller, October 18, 1950 Introduction.-All bacteria require for growth the presence of certain inorganic chemical components in the nutrient, such as potassium, phos- phorus, sulphur, etc., and with a few exceptions all bacteria require an energy-yielding carbon source, such as, for instance, glucose or lactate, etc. In addition to these elements or simple compounds, certain bacteria require more complex compounds, for instance an amino acid, which they are not capable of synthesizing. For the purposes of this presentation, any of the chemical compounds which a given strain of bacteria requires for its growth will be called a "growth factor." In general, the growth rate of a bacterial strain may be within very wide limits independent of the concentration of a given growth factor; but since at zero concentration the growth rate is zero, there must of necessity exist, at sufficiently low concentrations of the growth factor, a region in which the growth rate falls with falling concentration of the growth factor. It therefore should be possible to maintain a bacterial population over an indefinite period of time growing at a rate considerably lower than normal simply by maintaining the concentration of one growth factor-the controlling growth factor-at a sufficiently low value, while the concentrations of all other growth factors may at the same time be main- tained at high values.
    [Show full text]
  • Updated November 2019 KIT Mutation the KIT Gene Is Associated With
    Updated November 2019 KIT Mutation The KIT gene is associated with autosomal dominant piebaldism, gastrointestinal stromal tumors (GISTs), and familial mastocytosis.1-3 The type of mutation identified in the KIT gene determines the symptoms/cancer risks that the individual may have. Pathogenic loss-of-function (LOF) mutations in the KIT gene are generally only associated with Piebaldism. However, pathogenic gain of function mutations in the KIT gene are associated with systemic mastocytosis and gastrointestinal stromal tumors.4,5 Piebaldism: This is a rare condition characterized by the patchy absence of melanocytes in certain areas of the skin and hair. Melanocytes produce the pigment melanin, which contributes to hair, eye, and skin color. The absence of melanocytes leads to patches of skin and hair that are lighter than normal. These unpigmented areas are typically present at birth and do not increase in size or number.6-8 Gastrointestinal stromal tumors (GIST): GISTs are tumors that occur in the gastrointestinal tract, most commonly in the stomach or small intestine. Small tumors may cause no signs or symptoms. However, some people with GISTs may experience pain or swelling in the abdomen, nausea, vomiting, loss of appetite, or weight loss. These tumors can be cancerous (malignant) or noncancerous (benign). Mastocytosis: This is a blood disorder that occurs when white blood cells called mast cells accumulate in one or more tissues (most commonly in the bone marrow). Mast cells normally trigger inflammation during an allergic reaction. When an environmental trigger activates mast cells, they release proteins that signal an immune response. In systemic mastocytosis, excess mast cells mean more proteins are being released in the tissues where the cells accumulate, leading to an increased immune response.
    [Show full text]
  • B-Cell Growth Factor
    Proc. Natl Acad. Sci. USA Vol. 79, pp. 7455-7459, December 1982 Immunology B-cell growth factor: Distinction from T-cell growth factor and B-cell maturation factor (B lymphocytes/T-cell hybridomas) TOMAS LEANDERSON*, ERIK LUNDGRENt, ERIK RUUTH*, HAKAN BORGt, HAKAN PERSSONt, AND ANTONIO COUTINHOt tLaboratory for Cell and Tissue Culture Research, *Institute of Pathology, and +Department of Immunology, UmeA University, S-901 87 UmeA, Sweden Communicated by Niels K. Jerne, July 12, 1982 ABSTRACT A T-cell hybridoma was derived by somatic cell We have initiated these studies by systematically screening hybridization between concanavalin A-activated BALB/c spleen hybridoma activities in different assays that measure either cells and the AKR thymoma BW 5147. Media conditioned by hy- growth or maturation ofall B lymphocytes, regardless ofclonal bridoma cells, even at high dilutions (1:1,000) support the growth specificity. We chose to study activated rather than resting B oflipopolysaccharide-stimulated B-cell blasts but not that ofT-cell cells because of the-overwhelming evidence that initiation of growth factor (TCGF)-reactive T-cells. This activity, herein des- cooperative B-cell responses requires direct cellular interaction ignated B-cell growth factor (BCGF), has a Mr of =20,000 and it (13, 14). In this report we describe a hybridoma clone secreting can readily be separated from TCGF (Mr "30,000) by gel filtra- a factor that supports growth but not maturation of lipopoly- tion. BCGF is constitutively produced by the hybridoma cells, it saccharide (LPS)-activated B-cell blasts and is devoid of is removed from conditioned media by incubation with target cells T-cell at +4°C, and it is equally effective on B-cell blasts carrying dif- growthfactor(TCGF) andT-cellreplacingfactor(TRF) activities.
    [Show full text]
  • Sunitinib Malate)
    Prescribing Information Update for SUTENT® (sunitinib malate) July 12, 2010 Dear Health Care Provider: Pfizer Oncology is committed to providing you with up-to-date information about SUTENT® (sunitinib malate) capsules. This letter is to inform you of an important update to the SUTENT prescribing information (PI). The following boxed warning and safety information has been added to the PI for SUTENT: WARNING: HEPATOTOXICITY Hepatotoxicity has been observed in clinical trials and post-marketing experience. This hepatotoxicity may be severe and deaths have been reported. WARNINGS and PRECAUTIONS Hepatotoxicity SUTENT has been associated with hepatotoxicity, which may result in liver failure or death. Liver failure has been observed in clinical trials (7/2281 [0.3%]) and post-marketing experience. Liver failure signs include jaundice, elevated transaminases and/or hyperbilirubinemia in conjunction with encephalopathy, coagulopathy, and/or renal failure. Monitor liver function tests (ALT, AST, bilirubin) before initiation of treatment, during each cycle of treatment, and as clinically indicated. SUTENT should be interrupted for Grade 3 or 4 drug-related hepatic adverse events and discontinued if there is no resolution. Do not restart SUTENT if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure. Safety in patients with ALT or AST >2.5 × ULN or, if due to liver metastases, >5.0 × ULN has not been established. In addition, the labeling includes a new Medication Guide that your patients will receive when SUTENT is dispensed. Pfizer maintains a global safety database, monitoring all clinical trials and reports of spontaneous adverse events. The incidence of liver failure referenced above is consistent with the very low rate of hepatic failure described in the clinical trials of sunitinib used to support original FDA registration in 2006.
    [Show full text]
  • Mechanism of Myeloid-Derived Suppressor Cell
    MECHANISM OF MYELOID-DERIVED SUPPRESSOR CELL ACCUMULATION IN CANCER AND SUSCEPTIBILITY TO REVERSAL BY SUNITINIB by JENNIFER SUSAN KO, M.D. Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Thesis Adviser: Dr. James H. Finke Department of Pathology CASE WESTERN RESERVE UNIVERSITY January, 2010 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis of Jennifer Susan Ko candidate for the Doctor of Philosophy degree*. (signed) Alan Levine Ph.D. David Kaplan M.D., Ph.D. Clark Distelhorst M.D. James Finke Ph.D. Charles Tannenbaum Ph.D. (date) October 12th, 2009 *We also certify that written approval has been obtained for any proprietary material contained therein. 2 TABLE OF CONTENTS Title Page 1 Signature Sheet 2 Table of Contents 3 List of Tables 6 List of Figures 7 Acknowledgements 9 List of Abbreviations 10 Abstract 14 Chapter 1: Introduction 16 Overview: Myeloid-derived suppressor cells in cancer: a novel therapeutic target. 16 Immunotherapy in cancer 16 Myeloid-derived suppressor cells limit immunotherapy 22 Myeloid-derived suppressor cells limit anti-angiogenic therapy 28 Multiple factors are implicated in MDSC formation 30 Vascular Endothelial Growth Factor 30 Stem Cell Factor 32 Granulocyte- and Granulocyte/Monocyte Colony Stimulating Factors 33 S100A9 and Inflammation 34 Intracellular signaling implicated in MDSC programming 36 3 Chapter 2: Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients 44 Statement
    [Show full text]
  • Human Transforming Growth Factor Α (TGF-Α)
    787 STOMACH Gut: first published as 10.1136/gut.51.6.787 on 1 December 2002. Downloaded from Human transforming growth factor α (TGF-α) is digested to a smaller (1–43), less biologically active, form in acidic gastric juice T Marchbank, R Boulton, H Hansen, R J Playford ............................................................................................................................. Gut 2002;51:787–792 Background: Transforming growth factor α (TGF-α) is a 50 amino acid peptide with potent prolifera- tive and cytoprotective activity present in gastric mucosa and juice. Aims: To determine the forms and biological activity of natural and recombinant TGF-α following incu- bation with acid pepsin. Patients: Human gastric juice was obtained under basal conditions from patients taking acid suppres- sants and from volunteers undergoing intragastric neutralisation. See end of article for Methods: Samples were analysed using mass spectroscopy and/or high pressure liquid chromatogra- authors’ affiliations phy with radioimmunoassay. Biological activity was determined using thymidine incorporation into rat ....................... hepatocytes and an indomethacin/restraint induced gastric damage rat model. α α Correspondence to: Results: TGF- 1–50 is cleaved to TGF- 1–43 by acid pepsin and this is the predominant form in normal Professor R J Playford, gastric juice. However, intragastric neutralisation or taking acid suppressants caused the predominant Gastroenterology Section, α α 3 form to be TGF- 1–50.TGF- 1–43 had only half of the ability to maximally stimulate [ H]thymidine incorpo- Imperial College School of α ration into primary rat hepatocytes (28 177 (1130) DPM/well for 2.16 nM TGF- 1–43 v 63 184 (3536) Medicine, Hammersmith α Hospital Campus, Du Cane DPM/well for TGF- 1–50; p<0.001).
    [Show full text]
  • (ALK) Rearrangement in Adult Renal Cell Carcinoma with Lung Metastasis: a Case Report and Literature Review
    2861 Case Report Anaplastic lymphoma kinase (ALK) rearrangement in adult renal cell carcinoma with lung metastasis: a case report and literature review Shengyu Zhou1, Guanxing Sun2, Jianwei Wang1, Hongtu Zhang1 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China; 2Department of Medical Oncology, Zaozhuang Municipal Hospital, Zaozhuang, China Correspondence to: Shengyu Zhou. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100021, China. Email: [email protected]. Abstract: Renal cell carcinoma (RCC) with anaplastic lymphoma kinase (ALK) rearrangement is rare, and the genetic profiles of the tumor have not been elucidated. Here, we report a case with recurrent papillary RCC and lung metastasis after nephrectomy for nearly 7 years. The patient first received sunitinib, whereas the drug toxicity was intolerable. Combined Immunohistology (IHC) and fluorescence in situ hybridization (FISH) revealed the patient has an ALK rearrangement, and the patient then was treated with crizotinib. The patient had good tolerance, and a partial response in the target lesions was achieved. In order to further understand the benefit of crizotinib in ALK-rearranged RCC, the patient was detected with whole exome sequencing (WES) to study her genetic profiles. Compared those of RCC cases without ALK rearrangement (nALK-RCC), the patient and nine RCC cases with ALK rearrangement (ALK-RCC) revealed unique genetic characteristics: 1) The common mutations that occurred in RCC were not found in ALK-RCC.; 2) A total of 11 co-existing mutations in ALK-RCC were found, and they occurred in nALK-RCC at a relatively low frequency.
    [Show full text]